OBI Pharma to Sponsor Adagloxad Simolenin Satellite Symposium at the 2016 ESMO Annual Meeting

Experts Examine the Future of Active Immunotherapy in Oncology and the potential role of Adagloxad Simolenin (OBI-822)

TAIPEI, TAIWAN, September 6, 2016 – OBI Pharma, Inc., a Taiwan biotech company (TPex: 4174), today announced that it will host an industry-sponsored satellite symposium at the 2016 European Society for Medical Oncology (ESMO) Annual Meeting in Copenhagen, Denmark, to be held October 7-11, 2016. The symposium “Novel Approaches to Active Immunotherapy in Oncology – Targeting Globo Series with Adagloxad Simolenin” will review the data on targeting Globo Series antigens in Metastatic Breast Cancer cancers with the investigational active immunotherapy Adagloxad Simolenin (formerly OBI-822) and examine the future of active immunotherapy in oncology.

The symposium will be moderated by Stephen Johnston, MA, PhD, FRCP, Professor of Breast Cancer Medicine and Medical Oncologist at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research in London.

Date: Monday, October 10, 2016
Time: 6:30 p.m. to 8:00 p.m. CEST
Location: Athens Auditorium at the Bella Center in Copenhagen

Presenters will include:

  • Chiun-Sheng Huang, MD, Professor of Surgery and Director of The Breast Center at the National Taiwan University Hospital and the National Taiwan University College of Medicine
  • Heather L. McArthur, MD, MPH, Medical Oncologist at Memorial Sloan Kettering Cancer Center
  • Chi-Huey Wong, PhD, Professor of Chemistry at The Scripps Research Institute, Past President Academia Sinica

“OBI Pharma is pleased to host this educational symposium at the prestigious ESMO meeting to discuss the future of active immunotherapy in oncology and the role of Adagloxad Simolenin, a novel first-in-class active immunotherapy,” said Amy Huang, General Manager of OBI Pharma. “OBI is committed to continuing the development of Adagloxad Simolenin for patients with Metastatic Breast Cancer and other cancers.”

The symposium is open to all ESMO attendees. Pre-registration is required online at Dinner will be included.

A Chinese translation of this release can be found here:

About Adagloxad Simolenin (OBI-822) and OBI-821
Adagloxad Simolenin (formerly OBI-822) is a new first-in-class, investigational anti-cancer treatment that belongs to a novel class of active immunotherapies which target the Globo Series antigens (Globo H, SSEA-3 and SSEA-4). Adagloxad Simolenin is a synthetic glycoprotein comprised of a Tumor-Associated Carbohydrate Antigen (TACA), Globo H, covalently bound to a carrier protein, Keyhole Limpet Hemocyanin. OBI-821 is a saponin-based adjuvant. Globo Series antigens are expressed in high levels on the surface of malignant tumors in many epithelial cancers, such as breast, prostate, gastric, lung, colon, pancreatic, and ovarian cancer, among others. The immunogenicity of the antigen is enhanced by conjugating Globo H to the KLH carrier protein to form Adagloxad Simolenin (Globo H-KLH), and then co-administering it with the adjuvant, OBI-821. OBI Pharma recently completed a Phase 2 International efficacy and safety study in 349 patients with Metastatic Breast Cancer. Adagloxad Simolenin is exclusively licensed to OBI Pharma from Memorial Sloan-Kettering Cancer Center (MSKCC).

About OBI Pharma
OBI Pharma, Inc. is a Taiwan biopharmaceutical company that was established in 2002. Its mission is to develop novel therapeutic agents for unmet medical needs, including cancer and infectious diseases. The company’s flagship product is Adagloxad Simolenin (formerly OBI-822), a first-in-class active immunotherapy for metastatic breast cancer. OBI is also developing next generation active immunotherapies for difficult to treat cancers, including lung, prostate, pancreatic, stomach, and ovarian cancer. Additional information can be found at

Forward-Looking Statements
Statements included in this press release that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about future clinical trials, results and the timing of such trials and results. Such risk factors are identified and discussed from time to time in OBI Pharma’s reports and presentations, including OBI Pharma’s filings with the Taiwan Securities and Exchange Commission.


Sharon Lee
OBI Pharma, Inc.
+886 (2) 2786-6589